DHA LABORATORY

Sample Patient

		Date of Birth:	**Gender:**
Specimen ID:	**Control ID:**	**Account Number:**	**Status:**
Specimen Details:		**Physician Details:**	
Collection Date:	**Patient ID:**	**Provider:**	
Report Date:	**Alt. Patient ID:**	**NPI Number:**	

Ordered Items: Ceruloplasmin; Comp. Metabolic Panel (14); Copper, Serum; Histamine Determination, Blood; Homocyst(e)ine; Plasma Zinc; TSH; Vitamin D, 25-Hydroxy

Test Name	Result	LabCorp Reference Range	Result	Walsh/Pfeiffer Functional Range	Flag	Units	Lab
Ceruloplasmin							
• Ceruloplasmin	19	16.0-31.0				mg/dL	01
Comp. Metabolic Panel (14)							
• Glucose	68	70-99			Low	mg/dL	01
• BUN	17	6-24				mg/dL	01
• Creatinine	1.02	0.76-1.27				mg/dL	01
• eGFR	91	>59				mL/min/1.73	01
• BUN/Creatinine Ratio	17	9-20					01
• Sodium	143	134-144				mmol/L	01
• Potassium	4	3.5-5.2				mmol/L	01
• Chloride	103	96-106				mmol/L	01
• Carbon Dioxide, Total	24	20-29				mmol/L	01
• Calcium	9.1	8.7-10.2				mg/dL	01
• Protein, Total	6.4	6.0-8.5				g/dL	01
• Albumin	4.4	4.0-5.0				g/dL	01
• Globulin, Total	2	1.5-4.5				g/dL	01
Bilirubin, Total	0.6	0.0-1.2				mg/dL	01
• Alkaline Phosphatase	132	44-121			High	IU/L	01
• AST (SGOT)	45	0-40			High	IU/L	01
• ALT (SGPT)	53	0-44			High	IU/L	01
Copper, Serum							
• Copper, Serum	104	69-132	104	70-110		ug/dL	02
Detection Limit = 5							
Histamine Determination, Blood							
• Histamine Determination, Blood	37	12-127	37	40-70		ng/mL	02

DHA Laboratory
411 E Business Center Dr #107, Mt Prospect, IL 60056

Email: info@dhalab.com | **Phone**: 847-222-9546 | **Fax**: 847-222-9547

Test Name	Result	LabCorp Reference Range	Result	Walsh/Pfeiffer Functional Range	Flag	Units	Lab
Results for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.							
Homocyst(e)ine							
• **Homocyst(e)ine**	**8.4**	0.0-14.5				umol/L	01
Plasma Zinc							
• **Plasma Zinc**	**93**	56-134	**93**	90-135		ug/dL	02
Detection Limit = 5							
TSH							
• **TSH**	**1.95**	0.450-4.500				uIU/mL	01
Vitamin D, 25-Hydroxy							
• **Vitamin D, 25-Hydroxy**	**52.6**	30.0-100.0				ng/mL	01

Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2).
1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press.
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.

DHA Laboratory
411 E Business Center Dr #107, Mt Prospect, IL 60056

Email: info@dhalab.com | **Phone**: 847-222-9546 | **Fax**: 847-222-9547

***NOTE:** The reference range(s) listed on this report are different than functional ranges. When determining biochemical imbalances based on the Carl Pfeiffer M.D./William Walsh Ph.D. model; Optimal functional ranges represent a range within a reference range that can position a patient within biochemical classes: (1) elevated histamine (2) low histamine (3) excess copper (4) zinc deficiency. Optimal functional ranges for patients may vary based on diagnosis, clinical features and response to treatment.

Laboratory Director: Judith Bowman, MD | CLIA #: 14D0995837

Reference Testing Facilities:

Lab	Lab Name and Address	Lab Phone Numbers	Lab Medical Director
01	Labcorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego CA 921284108	8586683700	Galloway, Jenny R MD
02	Labcorp Burlington, 1447 York Court, Burlington NC 272153361	8007624344	Nagendra, Sanjai MD

DHA LABORATORY

LABORATORY REPORT

Kryptopyrrole / Hydroxyhemopyrrolin-2-one (HPL)

Quantitative Urine Report

DHA LABORATORY | CLIA # 14D0995837

RESULT

5.10

mcg/dL

Optimal

PATIENT INFORMATION

PATIENT LAST NAME	FIRST NAME	M.I.	DATE OF BIRTH
Last name	First name	M.I.	mm/dd/yyyy

SEX: ◯ Male ◯ Female

PRACTITIONER: Dr.

DATES

DATE TESTED	DATE / TIME COLLECTED	DATE REPORTED
mm/dd/yyyy	mm/dd/yyyy, --:-- --	mm/dd/yyyy

COLLECTION NOTES

- ☐ Patient not taking supplements for 12–24 hours prior to testing
- ☐ Patient taking supplements for 12–24 hours prior to testing
- ☐ Additional Comments: Enter comments here...

TEST RESULT

Procedure: Kryptopyrrole (Hydroxyhemopyrrolin-2-one (HPL))

RESULT

5.10 mcg/dL

SPECIFIC GRAVITY

1.011

● **Result is within Optimal range (0–10.99 mcg/dL)**



CLASSIFICATION	RANGE
OPTIMAL	0–10.99 mcg/dL
BORDERLINE	11–15.99 mcg/dL
ELEVATED	≥ 16 mcg/dL

Pyrroles can vary based on the concentration of urine. This Kryptopyrrole result compensates for the concentration of the urine specimen.

Judith Bowman MD
Laboratory Director

T 847.222.9546 | F 847.222.9547
E results@dhalab.com
W www.DHALab.com

DHA LABORATORY

LABORATORY REPORT

Kryptopyrrole / Hydroxyhemopyrrolin-2-one (HPL)

Quantitative Urine Report

DHA LABORATORY | CLIA # 14D0995837

CLINICAL PATHWAY — ELEVATED KRYPTOPYRROLE



Additional Clinical Manifestations

- Hair Loss
- Dry eyes
- White Spots on Fingernails
- Impaired Immune functions
- Skin Rash
- Slow Growth/Delayed puberty
- Fatigue
- Anemia
- Nerve Problems (Pins and needles) in hands and feet
- Poor Wound Healing
- Poor Stress control
- Abnormal fat distribution
- "Fruity" breath and/or Body odor
- Morning Nausea
- Spleen-area Pain
- Joint pains
- Sensitivity to light and Noise
- Preference for spicy foods

KEY

- Clinical Manifestations of Pyrrole Disorder
- Elevated
- Decreased
- Neurotransmitter
- Fatty Acids Nutrient - Relationship
- Ionotropic Glutamate Receptor
- (Co)Enzyme/Vitamin

RETESTING SCHEDULE

TEST	RECOMMENDATION
Kryptopyrrole Quantitative Urine	3–4 Months

These findings should be evaluated in the context of the patient's comprehensive clinical profile, including relevant history and presenting symptoms, and are subject to the interpretive judgment of the treating medical professional.

Judith Bowman MD
Laboratory Director

T 847.222.9546 | F 847.222.9547
E results@dhalab.com
W www.DHALab.com